Average Clinical Testing Period by Therapeutic Category​

This is from a paper that talks about why we need to change the system. It kind of mirrors what we talked about on the speed of development on drugs and other items from companies like OPKO. If you lose the additional year development lose a year of exclusivity selling.

In medicine today, we face an innovation paradox. The companies that develop new medicines are highly dependent on a period of exclusive marketing after approval, to fund their research and development programs. But longer research and development programs are not associated with longer periods of exclusive marketing. Instead the period of exclusive marketing may be shorter. Exclusivity that dwindles with each additional month of pre-commercialization research would ordinarily lead innovators to be more efficient, but the added factor of the drug regulatory system leads to a different result. In this system, the length of any particular premarket program turns largely on considerations not within the firm’s control.


poseidon01.ssrn.com/delivery.php?ID=590021110103114116065112079078083089033045032063002023097008103106064117093025013023018006111123006038051125024066114086114079014034002059078079116117099029026024017005051081091085065119001085006113031015125127124027016010079114005006096084031087086&EXT=pdf